219 related articles for article (PubMed ID: 26681989)
41. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
42. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation.
Hiraga T; Ito S; Nakamura H
Int J Cancer; 2016 Apr; 138(7):1698-708. PubMed ID: 26576938
[TBL] [Abstract][Full Text] [Related]
43. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
44. B-cell receptor-associated protein 31 regulates human embryonic stem cell adhesion, stemness, and survival via control of epithelial cell adhesion molecule.
Kim WT; Seo Choi H; Min Lee H; Jang YJ; Ryu CJ
Stem Cells; 2014 Oct; 32(10):2626-41. PubMed ID: 24898727
[TBL] [Abstract][Full Text] [Related]
45. Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model.
Zhou K; Huo X; Nguyen R; Bae SDW; Han S; Zhang Z; Duan W; Yuen L; Lam V; George J; Qiao L
J Control Release; 2022 Jan; 341():341-350. PubMed ID: 34848243
[TBL] [Abstract][Full Text] [Related]
46. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
47. Single molecular recognition force spectroscopy study of a DNA aptamer with the target epithelial cell adhesion molecule.
Wang N; Liu H; Hao J; Bai X; Li H; Zhang Z; Wang H; Tang J
Analyst; 2015 Sep; 140(18):6226-9. PubMed ID: 26229987
[TBL] [Abstract][Full Text] [Related]
48. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner.
Yan B; Stantic M; Zobalova R; Bezawork-Geleta A; Stapelberg M; Stursa J; Prokopova K; Dong L; Neuzil J
BMC Cancer; 2015 May; 15():401. PubMed ID: 25967547
[TBL] [Abstract][Full Text] [Related]
49. Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells.
Macdonald J; Denoyer D; Henri J; Jamieson A; Burvenich IJG; Pouliot N; Shigdar S
Nucleic Acid Ther; 2020 Apr; 30(2):117-128. PubMed ID: 32027209
[TBL] [Abstract][Full Text] [Related]
50. Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
Sanomachi T; Suzuki S; Kuramoto K; Takeda H; Sakaki H; Togashi K; Seino S; Yoshioka T; Okada M; Kitanaka C
Anticancer Res; 2017 Nov; 37(11):6177-6188. PubMed ID: 29061799
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles.
Yang Y; Gao Y; Chen L; Huang Y; Li Y
Int J Pharm; 2011 Feb; 405(1-2):188-95. PubMed ID: 21130850
[TBL] [Abstract][Full Text] [Related]
52. Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo.
Zhang K; Li Y; Liu W; Gao X; Zhang K
Mol Med Rep; 2015 Jan; 11(1):639-44. PubMed ID: 25333812
[TBL] [Abstract][Full Text] [Related]
53. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
54. Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma.
Pilapong C; Sitthichai S; Thongtem S; Thongtem T
Int J Pharm; 2014 Oct; 473(1-2):469-74. PubMed ID: 25089503
[TBL] [Abstract][Full Text] [Related]
55. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
56. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells.
Karimi-Busheri F; Zadorozhny V; Li T; Lin H; Shawler DL; Fakhrai H
J Stem Cells; 2011; 6(1):9-20. PubMed ID: 22997842
[TBL] [Abstract][Full Text] [Related]
57. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
[TBL] [Abstract][Full Text] [Related]
58. The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer.
Shigdar S; Qian C; Lv L; Pu C; Li Y; Li L; Marappan M; Lin J; Wang L; Duan W
PLoS One; 2013; 8(2):e57613. PubMed ID: 23460885
[TBL] [Abstract][Full Text] [Related]
59. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model.
Alshaer W; Hillaireau H; Vergnaud J; Mura S; Deloménie C; Sauvage F; Ismail S; Fattal E
J Control Release; 2018 Feb; 271():98-106. PubMed ID: 29277682
[TBL] [Abstract][Full Text] [Related]
60. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
